The increase in β-OHB levels by the administration of SGLT-2 inhibitors seems to be an alternative source of energy for the myocyte in conditions such as heart failure by changing the energy environment of the cell in a favorable way while promoting a reduction in the size of the heart infarct in ischemia–reperfusion injury (I/R injury). The gene discussed is SLC5A2; the disease is heart failure.